WUXI ADVANCED THERAPIES
Accelerating the Progress and Time to Market of Bio-Based Drugs through Integrated Manufacturing and Laboratory Testing Services Our Story By leveraging platforms and integrated testing, the Advanced Therapies business unit of WuXi AppTec is a streamlined Contract Development and Manufacturing Organization (CDMO), pioneering the expedited development and commercialization of cell, gene, protein and viral-based therapies. This approach enables new biopharmaceuticals to be developed, manufactured... and released faster and with greater predictability, thereby reducing the complexities of high-touch, multi-vendor production models. Our solutions help clients overcome challenges to commercialization, including process development, manufacturing capacity, analytical development, and raw materials management. Multiple, scale-able, enabling platforms integrate manufacturing, process development and testing capabilities to provide greater predictability and speed to clinic. Well positioned for growth, our investments in personnel and manufacturing continue to expand clinical and commercial capacities. Since 2004, WuXi AppTec has supported Advanced Therapy programs with an extensive infrastructure of state-of-the-art, GMP-compliant facilities, providing centers of excellence for manufacturing and testing. Our Vision To significantly contribute to the growth of Advanced Therapies by accelerating and transforming development and manufacturing through our enabling platforms and technologies to the benefit of patients worldwide.
WUXI ADVANCED THERAPIES
Industry:
Biotechnology Life Science Manufacturing Outsourcing Pharmaceutical Product Research Quality Assurance
Founded:
2004-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.advancedtherapies.com
Total Employee:
501+
Status:
Active
Contact:
215-218-7100
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress
Similar Organizations
Grand River Aseptic Manufacturing
Grand River Aseptic Manufacturing is a parenteral contract development and manufacturing organization.
Current Employees Featured
Official Site Inspections
http://www.advancedtherapies.com Semrush global rank: 836.36 K Semrush visits lastest month: 45.77 K
- Host name: 141.193.213.11
- IP address: 141.193.213.11
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "WuXi Advanced Therapies"
About Us - WuXi Advanced Therapies
WuXi Advanced Therapies is a Contract Testing, Development and Manufacturing Organization (CTDMO). We offer technology platforms and services that enable the discovery, โฆSee details»
WuXi Advanced Therapies
Development and Manufacturing Organization (CTDMO) offering integrated platforms to transform the discovery, development, testing, manufacturing, and commercialization of cell and gene โฆSee details»
WuXi Advanced Therapies - LinkedIn
WuXi Advanced Therapies - Accelerating Progress and Time to Market WuXi Advanced Therapies is a cell and gene therapy Contract Testing, Development and Manufacturing Organization (CTDMO) that is ...See details»
WuXi Advanced Therapies - Crunchbase Company โฆ
Contact Email [email protected]; ... the Advanced Therapies business unit of WuXi AppTec is a streamlined Contract Development and Manufacturing Organization (CDMO), pioneering the expedited. development โฆSee details»
WuXi ATU Opens New Manufacturing Facility to Further ... - WuXi โฆ
Oct 17, 2021 WuXi ATU is a leading Contract, Testing, Development and Manufacturing Organization (CTDMO) headquartered in Philadelphia. As its fourth manufacturing site โฆSee details»
WuXi Advanced Therapies Receives FDA Approval to โฆ
Feb 16, 2024 As the advanced therapies business unit of WuXi AppTec, WuXi Advanced Therapies is a Contract Testing, Development and Manufacturing Organization (CTDMO) that offers advanced platforms and end-to ...See details»
WuXi Advanced Therapies Expands Philadelphia Campus with
Nov 17, 2020 Our services and solutions accelerate time to market and support customer programs around the world. For more information, please visit: www.advancedtherapies.com . โฆSee details»
WuXi Advanced Therapies and A*STAR announce partnership to โฆ
Through its unique business models, WuXi AppTecโs integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), โฆSee details»
WuXi Advanced Therapies Announces Licensing Agreement with โฆ
Aug 12, 2022 As a Contract Testing, Development and Manufacturing Organization (CTDMO) with global operations, WuXi ATU will continue to enhance its capability and capacity to help โฆSee details»
WuXi Advanced Therapies Receives FDA Approval to ... - WuXi โฆ
Feb 19, 2024 For more information visit www.advancedtherapies.com. About WuXi AppTec. ... Development and Manufacturing Organization), helping customers improve the productivity of โฆSee details»
WuXi ATU Opens New Facility in Philadelphia, Tripling ... - WuXi โฆ
Nov 14, 2021 The new facility, which includes 140,000 square feet laboratories, will further enhance the companyโs Contract Testing, Development and Manufacturing Organization โฆSee details»
WuXi ATU and T-MAXIMUM Announce Strategic Partnership of โฆ
June 6, 2023 โ Boston, Massachusetts. WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and T-MAXIMUM today โฆSee details»
WuXi Advanced Therapies Receives FDA Approval to Manufacture โฆ
Feb 20, 2024 AMTAGVI is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer.. PHILADELPHIA, Feb. 20, 2024 /PRNewswire/ -- โฆSee details»
WuXi Advanced Therapies Expands Services to Include High
November 12, 2020 โ Philadelphia, PA - WuXi Advanced Therapies Inc. (WuXi ATU) today announced the expansion of its Cell & Gene Therapy Platforms with capabilities to provide โฆSee details»
WuXi Advanced Therapies Receives FDA Approval to Manufacture โฆ
Feb 20, 2024 AMTAGVIโข is the first and only one-time, individualized T cell therapy to receive U.S. FDA approval for a solid tumor cancer.. PHILADELPHIA, PA. February 20, 2024 โ WuXi โฆSee details»
WuXi ATU Announces Launch of TESSAโข Technology to ... - WuXi โฆ
Mar 7, 2022 As a Contract Testing Development and Manufacturing Organization (CTDMO) with operations globally, WuXi ATUโs unique business model integrates powerful testing โฆSee details»
WuXi Advanced Therapies and A*STAR announce partnership
28 April 2022 โ SINGAPORE. WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, and A*STARโs Bioprocessing Technology Institute (BTI), announced a new โฆSee details»
WuXi Advanced Therapies and A*STAR announce partnership ... - a โฆ
Apr 28, 2022 www.advancedtherapies.com WuXi Advanced Therapies and A*STAR announce partnership to advance cell and gene therapy in the Asia-Pacific region ... Organization), โฆSee details»